依达拉奉联合奥扎格雷钠治疗急性脑梗死临床疗效对照

目的观察并分析依达拉奉联合奥扎格雷钠对于急性脑梗死患者的临床疗效及其不良反应。方法将2007年--2011年期间本院收治的66例急性脑梗死患者作为临床研究对象，按照治疗方案的不同分为联合用药组（简称联合组）和对照组，联合组给予依达拉奉联合奥扎格雷钠治疗，对照组单用奥扎格雷钠。结果2组患者均疗效显著，但联合组疗效、NIHSS评分以及血清超敏c反应蛋白（hs—CRP）、同型半胱氨酸（Hey）、超氧化物歧化酶（SOD）以及丙二醛（MDA）水平改善情况均显著优于对照组，2组不良反应无显著差异。结论依达拉奉联合奥扎格雷钠治疗急性脑梗死患者疗效显著，优于奥扎格雷钠单用，值得广为推荐。

Clinical efficacy of edaravone combined with ozagrel sodium in the treatment of acute cerebral infarction

Objective To observe and analyze the clinical efficacy and adverse reactions of edaravone combined with ozagrel sodium for patients with acute cerebral infarction （ACI）. Methods Sixty-six ACI patients who were admitted to our hospital from 2007 to 2011 were included in the study. They were divided into two groups according to difference treatment schemes. The com- bined group received edaravone combined with sodium ozagrel while the control group only received ozagrel sodium. Results Both groups achieved good outcomes. But the efficacy of the combined group, the improvement of NIHSS score, and serum high sensitivity C- reactive protein （hs- CRP）, homocysteine （Hcy）, superoxide dismutase （SOD）, and malondialdehyde （MDA） levels were significantly better in the combined group than in the control group. Adverse reactions showed no statistically significant difference. Conclusion Edaravone combined with ozagrel sodium is better in the treatment of acute cerebral infarction. Thus it is worthy of clinical promotion.